Company / Financials
Apellis Pharmaceuticals, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.0B
FY2025 · +28.5% YoY
Net Income
$22.4M
FY2025 · +111.3% YoY
Profit Margin
2.2%
FY2025 · net income / revenue
ROE
6.0%
FY2025 · return on equity
Total Assets
$1.1B
FY2025
Total Debt
-
FY2025
Equity
$370.1M
FY2025
ROA
2.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.0B+28.5% YoYNet Income HistoryProfit after all expenses and taxes$22.4M+111.3% YoYOperating Income HistoryProfit from core business operations before interest and taxes$55.4M+133.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$550.3M+9.8% YoYR&D Expense HistoryResearch and development spending$295.9M-9.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$5.7MIncome Tax HistoryTotal income tax expense$1.7M+48.2% YoYEPS (Basic) HistoryBasic earnings per share-$4.45+27.6% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$4.45+27.6% YoYShares Outstanding HistoryWeighted average diluted shares outstanding124.5M+4.1% YoY